Naltrexone

Naltrexone is an opioid antagonist medication that works by blocking the effects of opioids. Patients taking naltrexone receive a monthly injection, which reduces cravings for heroin/opioids and also blocks the brain’s opioid receptors from the patient feeling any euphoric effects should they impulsively use heroin. Naltrexone cannot be administered to a patient until he or she has been totally withdrawn from opioids (a procedure known as detoxification) and has been opioid-free for at least 7 days. Naltrexone prevents relapse and can also be used by patients who have been in treatment and have tapered off buprenorphine as an added protection against relapse.

Related Training Resources

Format: Module
Interactive, SCORM-based Activity
Opioid use disorder (OUD) has highly effective FDA-approved medications for its treatment. This course reviews and compares pharmacological treatment options for individuals with OUD, including methadone, buprenorphine (sublingual and injectable formulations), and naltrexone (oral and long-acting intramuscular formulations). Current evidence for each medication is reviewed in detail, and studies comparing each are discussed. The purpose and goal of medications for OUD are reviewed, and different treatment models are presented. The course includes case vignettes in which medication options for OUD are considered.
Presenter(s):
Melissa B. Weimer, DO, MCR, DFASAM
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Module
Interactive, SCORM-based Activity
Other substance use disorders can often co-occur with opioid use disorder (OUD). These can include benzodiazepines and other tranquilizers, cocaine and stimulants, and cannabis. Alcohol and nicotine are also considered commonly used substances alongside opioids. In this educational activity, these other substances will be reviewed leading to a discussion of principles of diagnosis and evaluation of treatment for each substance by themselves, and in the context of OUD.
Presenter(s):
Edward V. Nunes, MD
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Module
Substance Use disorders in Older Adults is a growing problem not only in the United States but throughout the developed world. The Baby Boomer generation, born between 1946 and 1964 is turning 58-76 years old this year. This group is presenting with more Substance Use Disorders and need for substance use treatment now. The use of an artificial cut off age of 65 years of age as the definition of elderly or old is somewhat arbitrary and this will be discussed. The module will look at the prevalence, screening and treatment of tobacco, alcohol, opioids, non-medical use of prescription drugs and illicit opioids as well as stimulants and cocaine, marijuana and non-opioid sedative hypnotic agents. A case vignette will drive the CME portion and elucidate the tenants of the module.
Presenter(s):
Louis A. Trevisan, MD, MEd, Associate Professor, Adjunct, Yale University School of Medicine
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Webinar
This webinar will explore the intersection of substance use and veteran status, examining the impact of post-traumatic stress, moral injury, and systemic barriers to care. Participants will learn about evidence-based interventions, and resources available to veterans.
Presenter(s):
Dr. Pilar Horner, MSW, PhD; Tina Thompson, MSW, LMSW; and Scott Saghy, MSW; U.S. Army veteran, social worker
Credit Available:
CE Credit(s): Yes
Designations: 1 ASWB ACE Credit
Format: Webinar
According to the Substance Abuse and Mental Health Services Administration, in 2019, only 10% of adults in the U.S with any substance use disorder (SUD) received treatment in part because effective evidence-based treatments for SUDs can be difficult to access in many communities.  CCBHCs help address this issue, delivering easily accessible and effective outpatient behavioral health care and SUD treatment through activities including expanded operating hours, same-day and walk-in appointments, outreach to sidelined populations and moving service delivery beyond clinic walls to reach people in their homes and in the community.
Presenter(s):
Lowell Robertson, MD, GRAND Mental Health; Kim Hill-Crowell, LCSW, GRAND Mental Health
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, Nursing contact hours, AAPA Category 1 CME credit, Social Work CE Credit, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Webinar
Over 2.5 million adults in the U.S. are diagnosed with OUD. In 2022, 12.7% of ED visits involved opioids. Yet only 25% of those who need treatment receive recommended MOUD. MOUDs are highly effective treatments that have been shown to decrease opioid use, cravings and transmission of infectious disease, and to increase retention in treatment. As the opioid epidemic continues to impact people across the U.S., the ED represents a critical access point to the health care system, supporting people with OUD by initiating MOUD, such as buprenorphine, and connecting them to low-threshold, easy-to-access care for continued treatment.
Presenter(s):
Arianna Campbell, DMSc, MPH, PA-C
Credit Available:
CE Credit(s): No
Certificate: Certificate of Attendance, 1-hour
Loading more

SAMHSA has developed a Buprenorphine Quick Start Guide for practitioners looking to prescribe buprenorphine.

Related Training Resources

Format: Podcast
This episode examines how these newer compounds differ pharmacologically, why they are more dangerous, and how clinicians can recognize and respond to kratom-related harms. Listeners will gain practical strategies for identifying kratom use disorder, managing withdrawal, and having informed, non-stigmatizing conversations with patients as these products continue to emerge and change.
Presenter(s):
Arianna Campbell, DMSc, MPH, PA-C, CAQ-EM, DFAAPA; Josh Luftig,PA-C; and Kathryn Hawk, MD, MHS
Credit Available:
CE Credit(s): No
Certificate: No
Format: Module
Interactive, SCORM-based Activity
Patient-centered care has become a crucial approach when working with patients with substance use disorder (SUD). Unfortunately, the care continuum can be interrupted for patients with SUDs, often due to stigma and discrimination. Each interruption increases challenges in access to care and can lead to patient harm. Language can intentionally or unintentionally perpetuate stigma. As people who care for patients with SUDs, we need to learn their rights so we can advocate for them and change our language to reduce stigma. This course will discuss the importance of patient-centered care, improved language when discussing substance use, and advocacy strategies that clinicians can use when caring for people who use substances.
Presenter(s):
Anna Maria South, MD, FACP, FASAM
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Module
Interactive, SCORM-based Activity
Opioid use disorder (OUD) has highly effective FDA-approved medications for its treatment. This course reviews and compares pharmacological treatment options for individuals with OUD, including methadone, buprenorphine (sublingual and injectable formulations), and naltrexone (oral and long-acting intramuscular formulations). Current evidence for each medication is reviewed in detail, and studies comparing each are discussed. The purpose and goal of medications for OUD are reviewed, and different treatment models are presented. The course includes case vignettes in which medication options for OUD are considered.
Presenter(s):
Melissa B. Weimer, DO, MCR, DFASAM
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Module
Interactive, SCORM-based Activity
This course discusses the importance of integrating opioid use disorder (OUD) pharmacotherapy into general medical settings, and describes models in primary care, emergency rooms, and hospitals where medications for OUD treatment are successfully included as standard care. Through reviews of OUD pharmacotherapy implementation in clinical practice, participants will learn how to adapt these strategies to their own settings. The course also introduces evidence-based counseling approaches to enhance motivation, treatment engagement, and sustained remission. Standard Medical Management (SMM) will be highlighted as an efficient, structured option readily incorporated into primary care. Participants are encouraged to adapt this information for use in their own clinical practices.
Presenter(s):
Laura Fanucchi, MD, MPH, FACP, FASAM
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Module
Interactive, SCORM-based Activity
Other substance use disorders can often co-occur with opioid use disorder (OUD). These can include benzodiazepines and other tranquilizers, cocaine and stimulants, and cannabis. Alcohol and nicotine are also considered commonly used substances alongside opioids. In this educational activity, these other substances will be reviewed leading to a discussion of principles of diagnosis and evaluation of treatment for each substance by themselves, and in the context of OUD.
Presenter(s):
Edward V. Nunes, MD
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit
Format: Webinar
Join our 4-session online case-based learning collaborative series focused on treating opioid use disorder. Delve into strategies to effectively assess and manage opioid withdrawal and explore real-world cases provided by addiction experts, applying knowledge to practical situations. Each session is presented live online and spans 1.5 hours. Designed for healthcare team members new to treating patients with opioid use disorder and opioid withdrawal, the series aims to offer additional insights, knowledge, and confidence. 
Presenter(s):
Andrew King, MD; and Kathryn Basques, MSW, APRN
Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, AAPA Category 1 CME, Nursing Contact Hours, Nursing Pharmacology Hours, NBCC Contact Hours (Counselors), NAADAC Contact Hours (SUD Counselor Credits), ASWB ACE Social Worker General Continuing Education Credits, Joint Accreditation Interprofessional Continuing Education (IPCE) Credits, CAADE Credits, CADTP Credits, CCAPP Credits, ABIM MOC Points, ABS MOC Points, ABA MOCA, ABP MOC Points, ABPM Continuing Certification
Loading more